Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Hwangryun-Haedok-Tang Fermented with Lactobacillus casei Suppresses Ovariectomy-Induced Bone Loss.

Shim KS, Kim T, Ha H, Cho CW, Kim HS, Seo DH, Ma JY.

Evid Based Complement Alternat Med. 2012;2012:325791. doi: 10.1155/2012/325791. Epub 2012 Oct 2.

2.

Lactobacillus fermentation enhances the inhibitory effect of Hwangryun-haedok-tang in an ovariectomy-induced bone loss.

Shim KS, Kim T, Ha H, Lee KJ, Cho CW, Kim HS, Seo DH, Ma JY.

BMC Complement Altern Med. 2013 May 16;13:106. doi: 10.1186/1472-6882-13-106.

4.

Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.

Wang L, Qiu XM, Gui YY, Xu YP, Gober HJ, Li DJ.

Drug Des Devel Ther. 2015 Jul 21;9:3755-66. doi: 10.2147/DDDT.S88512. eCollection 2015.

5.

KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.

Liou SF, Hsu JH, Lin IL, Ho ML, Hsu PC, Chen LW, Chen IJ, Yeh JL.

PLoS One. 2013 Jul 25;8(7):e69468. doi: 10.1371/journal.pone.0069468. Print 2013.

6.

Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways.

Hsiao HB, Lin H, Wu JB, Lin WC.

Osteoporos Int. 2013 May;24(5):1663-76. doi: 10.1007/s00198-012-2199-z. Epub 2012 Nov 10.

7.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

8.

Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.

Yuan FL, Xu RS, Jiang DL, He XL, Su Q, Jin C, Li X.

Bone. 2015 Jun;75:128-37. doi: 10.1016/j.bone.2015.02.017. Epub 2015 Feb 21.

PMID:
25708053
9.

Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling.

Thummuri D, Jeengar MK, Shrivastava S, Nemani H, Ramavat RN, Chaudhari P, Naidu VG.

Pharmacol Res. 2015 Sep;99:63-73. doi: 10.1016/j.phrs.2015.05.006. Epub 2015 May 28.

PMID:
26022736
10.

Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.

Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, Soh Y.

Eur J Pharmacol. 2013 Sep 5;715(1-3):96-104. doi: 10.1016/j.ejphar.2013.06.002. Epub 2013 Jun 19.

PMID:
23791609
11.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
12.

Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.

Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki M, Tang CH.

Eur J Pharmacol. 2008 Jun 24;588(1):124-33. doi: 10.1016/j.ejphar.2008.04.024. Epub 2008 Apr 16.

PMID:
18495114
13.

Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.

Kang MR, Jo SA, Yoon YD, Park KH, Oh SJ, Yun J, Lee CW, Nam KH, Kim Y, Han SB, Yu J, Rho J, Kang JS.

Mar Drugs. 2014 Nov 24;12(11):5643-56. doi: 10.3390/md12115643.

14.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

15.

The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.

Huh JE, Jung IT, Choi J, Baek YH, Lee JD, Park DS, Choi DY.

Eur J Pharmacol. 2013 Jan 5;698(1-3):57-66. doi: 10.1016/j.ejphar.2012.08.013. Epub 2012 Sep 14.

PMID:
22985747
16.

Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.

Narayana Murthy PS, Sengupta S, Sharma S, Singh MM.

J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):117-28. Epub 2006 Jun 21.

PMID:
16797179
17.

The hemoglobin receptor protein of porphyromonas gingivalis inhibits receptor activator NF-kappaB ligand-induced osteoclastogenesis from bone marrow macrophages.

Fujimura Y, Hotokezaka H, Ohara N, Naito M, Sakai E, Yoshimura M, Narita Y, Kitaura H, Yoshida N, Nakayama K.

Infect Immun. 2006 May;74(5):2544-51.

18.

Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.

Zhu L, Wei H, Wu Y, Yang S, Xiao L, Zhang J, Peng B.

Int J Biochem Cell Biol. 2012 Jul;44(7):1139-52. doi: 10.1016/j.biocel.2012.04.003. Epub 2012 Apr 12.

PMID:
22521613
19.

12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.

Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.

J Bone Miner Res. 2003 Dec;18(12):2159-68.

20.

Carbon monoxide protects against ovariectomy-induced bone loss by inhibiting osteoclastogenesis.

Van Phan T, Sul OJ, Ke K, Lee MH, Kim WK, Cho YS, Kim HJ, Kim SY, Chung HT, Choi HS.

Biochem Pharmacol. 2013 Apr 15;85(8):1145-52. doi: 10.1016/j.bcp.2013.01.014. Epub 2013 Feb 1.

PMID:
23380478

Supplemental Content

Support Center